- Home
- SSSS vs AVR Comparison
SSSS vs AVR Comparison
Compare SSSS & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- AVR
- Stock Information
- Founded
- SSSS 2010
- AVR 1999
- Country
- SSSS United States
- AVR Australia
- Employees
- SSSS N/A
- AVR N/A
- Industry
- SSSS Finance: Consumer Services
- AVR
- Sector
- SSSS Finance
- AVR
- Exchange
- SSSS Nasdaq
- AVR NYSE
- Market Cap
- SSSS 138.2M
- AVR 162.1M
- IPO Year
- SSSS N/A
- AVR 2024
- Fundamental
- Price
- SSSS $8.37
- AVR $3.17
- Analyst Decision
- SSSS Strong Buy
- AVR Strong Buy
- Analyst Count
- SSSS 3
- AVR 4
- Target Price
- SSSS $9.33
- AVR $16.50
- AVG Volume (30 Days)
- SSSS 261.6K
- AVR 319.9K
- Earning Date
- SSSS 08-06-2025
- AVR 08-16-2025
- Dividend Yield
- SSSS 61.57%
- AVR N/A
- EPS Growth
- SSSS N/A
- AVR N/A
- EPS
- SSSS N/A
- AVR N/A
- Revenue
- SSSS $3,644,430.00
- AVR $2,493,000.00
- Revenue This Year
- SSSS $5,400.03
- AVR $33.26
- Revenue Next Year
- SSSS N/A
- AVR $194.42
- P/E Ratio
- SSSS N/A
- AVR N/A
- Revenue Growth
- SSSS N/A
- AVR N/A
- 52 Week Low
- SSSS $3.52
- AVR $2.34
- 52 Week High
- SSSS $8.77
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- SSSS 67.40
- AVR N/A
- Support Level
- SSSS $8.31
- AVR N/A
- Resistance Level
- SSSS $8.35
- AVR N/A
- Average True Range (ATR)
- SSSS 0.36
- AVR 0.00
- MACD
- SSSS -0.02
- AVR 0.00
- Stochastic Oscillator
- SSSS 73.42
- AVR 0.00
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.